Fractionated 1927nm Laser for Hyperpigmentation
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dyspigmentation or scarring in this population.
Who Is on the Research Team?
Jeffrey Kenkel, MD
Principal Investigator
UT Southwestern- Department of Plastic Surgery
Are You a Good Fit for This Trial?
Adults aged 18-75 with darker skin tones (Fitzpatrick Skin Phototypes V and VI) who have noticeable hyperpigmentation on their face and are seeking treatment. Participants must be willing to avoid other aesthetic treatments, follow study procedures, use approved birth control if applicable, and not have any health conditions that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 1927nm non-ablative fractionated laser therapy for hyperpigmentation with treatments on Day 0, Day 30, and Day 60
Follow-up
Participants are monitored for changes in hyperpigmentation and adverse events at 1-month and 3-month follow-up visits
What Are the Treatments Tested in This Trial?
Interventions
- MOXI
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor